Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study

This study has been completed.

Sponsor:

Information provided by:

National University Hospital, Singapore

ClinicalTrials.gov Identifier:

NCT00452998

First received: March 27, 2007

Last updated: May 12, 2008

Last verified: May 2008

History of Changes

Purpose

Sequential Laser Iridotomy uses argon and Nd:yag laser in the first and second steps, respectively. Using q-switched 532 nm laser in the second step is hypothesized to be as good and effective as the conventional Nd:yag laser, because it selectively targets pigmented cells and delivers a short pulse duration of 3 nanoseconds, causing less thermal and collateral damage.

Condition	Intervention
Chronic Angle Closure Glaucoma Primary Angle Closure Primary Angle Closure Suspect Fellow Eyes of Acute Angle Closure Glaucoma	Procedure: Q-switched fd Nd:yag in Laser Iridotomy


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Neodymium

U.S. FDA Resources

Further study details as provided by National University Hospital, Singapore:

Primary Outcome Measures:

Visual Acuity
Intraocular pressure
Total power delivered by each laser modality
Iridotomy patency and size
Pain rating during the procedure
Anterior segment inflammation
Endothelial cell count
Cataract progression
Rate of complications


Estimated Enrollment:	10
Study Start Date:	November 2006
Study Completion Date:	December 2007
Primary Completion Date:	December 2007 (Final data collection date for primary outcome measure)

Show Detailed Description

Eligibility


Ages Eligible for Study:	22 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

More than 21 years old
Able to give informed consent
Diagnosis of either: chronic angle closure glaucoma (CACG), primary angle closure (PAC), primary angle closure suspect (PACS) or fellow eyes of acute angle closure glaucoma (AACG), and in need of a laser iridotomy

Exclusion Criteria:

History of any prior laser treatment or intraocular surgery to the eye
History of any corneal disease
Any ocular infection/ inflammation within the last two months
Inability to give informed consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00452998

Locations


Singapore
National University Hospital
Singapore, Singapore, 119074

Sponsors and Collaborators

National University Hospital, Singapore

Investigators


Principal Investigator:	Paul Chew, FRCSEd,MMed	National University Hospital, Singapore

More Information

Publications:

Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995 Apr;60(4):359-71.


Responsible Party:	Cecilia Aquino, MD, National University Hospital, Singapore
ClinicalTrials.gov Identifier:	NCT00452998 History of Changes
Other Study ID Numbers:	DSRB A/06/293
Study First Received:	March 27, 2007
Last Updated:	May 12, 2008
Health Authority:	Singapore: Health Sciences Authority

Keywords provided by National University Hospital, Singapore:


Sequential Laser Iridotomy Q-Switched 532 nm Laser Frequency Doubled Neodymium Yag Laser

Additional relevant MeSH terms:


Glaucoma Glaucoma, Angle-Closure Eye Diseases Ocular Hypertension

ClinicalTrials.gov processed this record on March 01, 2015

To Top